Japanese multi institutional study of Primovist-enhanced MRI for non-invasive diagnosis of HCC (JAMP-HCC study)
Phase 4
- Conditions
- hepatic carcinoma
- Registration Number
- JPRN-UMIN000011743
- Lead Sponsor
- Department of Radiology doctors' office, University of Yamanashi hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 450
Inclusion Criteria
Not provided
Exclusion Criteria
Step 1: Patients who meet any of the followingcriteria are not included in this study. 1. Patients who are judged to be inappropriate by the physician in charge Step 2: Patients who meet any of the following criteria are not included in this study. 1. Patients who are contraindicated or relatively contraindicated for iodine contrast agents and gadolinium contrast agents 2. Child-Pugh C 3. Patients with diffuse liver tumors 4. Patients who are judged to be inappropriate by the physician in charge (patients in terminal care, etc.)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diagnosability (sensitivity, specificity, PPV, NPV, and positive/negative likelihood ratio) using typical findings of HCC by EOB-enhanced MRI (low signal intensity in the hepatocyte phase plus other findings) is compared to that of dynamic CT
- Secondary Outcome Measures
Name Time Method